Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Retatrutide

TRIUMPH-1

Eli Lilly · Phase 3 · Completed · Enrollment 2335

NCT05929066

Y axis: Change in body weight from baseline, %

0-5-10-15-20-25048121620243648607284retatrutide 4 mg, week 80, -17.6%retatrutide 9 mg, week 80, -23.7%retatrutide 12 mg, week 80, -25%Placebo, week 80, -3.9%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • retatrutide 4 mg, one timepoint
  • retatrutide 9 mg, one timepoint
  • retatrutide 12 mg, one timepoint
  • Placebo, one timepoint
  • retatrutide 4 mg: week 80 -17.6%
  • retatrutide 9 mg: week 80 -23.7%
  • retatrutide 12 mg: week 80 -25%
  • Placebo: week 80 -3.9%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.